# Analysis Report

## Research Question:

"Are there specific drug ingredients or manufacturers that are disproportionately associated with drug recalls due to Current Good Manufacturing Practice (CGMP) deviations and impurity issues?"

## Interpretation and Insights on Returned Data:

Due to errors in the execution of `Analysis Query 2`, `Analysis Query 3`, and `Analysis Query 4`, the insights will be primarily drawn from `Analysis Query 1` and `Analysis Query 5`. These successful queries provide valuable information regarding recall trends over time and the categorization of recall reasons.

### Analysis Query 1: Recall Trend Over Time

This query aimed to analyze the monthly trends of drug recalls related to CGMP deviations and impurity issues. The results are presented in the table below:

**Table 1: Monthly Recall Trends for CGMP and Impurity Related Drug Recalls**

| Recall Month         | Monthly Recall Count | Previous Month Recall Count | Month-over-Month Change |
| -------------------- | -------------------- | ------------------------- | ----------------------- |
| 2025-02-01 00:00:00+08:00 | 1                    | 24                        | -23                     |
| 2025-01-01 00:00:00+08:00 | 24                   | 22                        | 2                       |
| 2024-12-01 00:00:00+08:00 | 22                   | 52                        | -30                     |
| 2024-11-01 00:00:00+08:00 | 52                   | 14                        | 38                      |
| 2024-10-01 00:00:00+08:00 | 14                   | 5                         | 9                       |
| 2024-09-01 00:00:00+08:00 | 5                    | 10                        | -5                      |
| 2024-08-01 00:00:00+08:00 | 10                   | 6                         | 4                       |
| 2024-07-01 00:00:00+08:00 | 6                    | 17                        | -11                     |
| 2024-06-01 00:00:00+08:00 | 17                   | 20                        | -3                      |
| 2024-05-01 00:00:00+08:00 | 20                   | 14                        | 6                       |
| 2024-04-01 00:00:00+08:00 | 14                   | 10                        | 4                       |
| 2024-03-01 00:00:00+08:00 | 10                   | 21                        | -11                     |
| 2024-02-01 00:00:00+08:00 | 21                   | 28                        | -7                      |
| 2024-01-01 00:00:00+08:00 | 28                   | 17                        | 11                      |
| 2023-12-01 00:00:00+08:00 | 17                   | 13                        | 4                       |
| 2023-11-01 00:00:00+08:00 | 13                   | 8                         | 5                       |
| 2023-10-01 00:00:00+08:00 | 8                    | 6                         | 2                       |
| 2023-09-01 00:00:00+08:00 | 6                    | 20                        | -14                     |
| 2023-08-01 00:00:00+08:00 | 20                   | 102                       | -82                     |
| 2023-07-01 00:00:00+08:00 | 102                  | 19                        | 83                      |
| 2023-06-01 00:00:00+08:00 | 19                   | 14                        | 5                       |
| 2023-05-01 00:00:00+08:00 | 14                   | 98                        | -84                     |
| 2023-04-01 00:00:00+08:00 | 98                   | 73                        | 25                      |
| 2023-03-01 00:00:00+08:00 | 73                   | 108                       | -35                     |
| 2023-02-01 00:00:00+08:00 | 108                  | 14                        | 94                      |
| 2023-01-01 00:00:00+08:00 | 14                   | 31                        | -17                     |
| 2022-12-01 00:00:00+08:00 | 31                   | 8                         | 23                      |
| 2022-11-01 00:00:00+08:00 | 8                    | 31                        | -23                     |
| 2022-10-01 00:00:00+08:00 | 31                   | 8                         | 23                      |
| 2022-09-01 00:00:00+08:00 | 8                    | 14                        | -6                      |
| 2022-08-01 00:00:00+08:00 | 14                   | 28                        | -14                     |
| 2022-07-01 00:00:00+08:00 | 28                   | 147                       | -119                    |

**Insights from Table 1:**

*   **Fluctuating Monthly Recalls:** The number of monthly recalls related to CGMP deviations and impurity issues shows significant fluctuation over time. There are months with very high recall counts (e.g., February 2023, July 2023) and months with very low counts (e.g., September 2022, October 2023, February 2025).
*   **No Clear Trend:**  There isn't a clear upward or downward trend in the number of recalls over the observed period. The month-over-month changes are inconsistent, suggesting that recalls are not steadily increasing or decreasing but rather occurring in peaks and troughs.
*   **Recent Decrease:** In the most recent months (January and February 2025), there is a notable decrease in recall counts, with February 2025 showing only one recall. However, it is too early to conclude if this signifies a sustained downward trend.
*   **Potential Seasonality or External Factors:** The fluctuations might be influenced by various factors such as increased regulatory scrutiny in certain periods, specific events triggering widespread recalls, or even seasonal variations in manufacturing practices. Further investigation would be needed to understand these patterns.

### Analysis Query 5: Recall Reason Category Breakdown

This query provided a breakdown of the reasons for drug recalls related to CGMP deviations and impurity issues, along with the percentage of total recalls each reason represents. The top recall reasons are presented in Table 2.

**Table 2: Top Recall Reasons for CGMP and Impurity Related Drug Recalls**

| Reason for Recall                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         | Recall Count | Percentage of Total Recalls |
| :------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ | :----------- | :-------------------------- |
| Microbial contamination                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | 465          | 8.48%                      |
| Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.                                                                                                                                                                                                                                 | 463          | 8.45%                      |
| CGMP Deviations: Intermittent exposure to temperature excursion during storage.                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 198          | 3.61%                      |
| CGMP Deviations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 174          | 3.17%                      |
| cGMP deviations: Temperature abuse                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 130          | 2.37%                      |
| cGMP deviations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 107          | 1.95%                      |
| CGMP Deviations: product held outside appropriate storage temperature conditions.                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 100          | 1.82%                      |
| Lack of assurance of sterility. Validation data for decontamination cycles is lacking.                                                                                                                                                                                                                                                                                                                                                                                                                                                                | 95           | 1.73%                      |
| Failed Impurities/Degradation Specifications                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 95           | 1.73%                      |
| CGMP Deviations: Firm went out of business and could no longer continue stability studies.                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 86           | 1.57%                      |
| Lack of Assurance of Sterility: There are also CGMP Deviations.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 81           | 1.48%                      |
| CGMP Deviations: recalling drug products following an FDA inspection.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 | 70           | 1.28%                      |
| cGMP Deviations                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 67           | 1.22%                      |
| CGMP Deviations: Lack of stability data and controls to support the manufacturers assigned retest or expiration date in firm's container/closure system.                                                                                                                                                                                                                                                                                                                                                                                         | 66           | 1.20%                      |
| CGMP Deviations: Carcinogen impurity detected in API used to manufacture drug product.                                                                                                                                                                                                                                                                                                                                                                                                                                                            | 65           | 1.19%                      |
| Cross Contamination With Other Products: Oral care solutions were manufactured by a third party supplier on equipment shared with non-pharmaceutical products                                                                                                                                                                                                                                                                                                                                                                                      | 64           | 1.17%                      |
| CGMP Deviations: Presence of NDMA impurity detected in product.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 53           | 0.97%                      |
| CGMP Deviations: Products were manufactured with contaminated excipient that was recalled from the excipient supplier.                                                                                                                                                                                                                                                                                                                                                                                                                              | 51           | 0.93%                      |
| CGMP Deviations: Firm did not adequately investigate customer complaints.                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 48           | 0.88%                      |
| Recalled products were made using an active ingredient that was recalled by a supplier due to penicillin cross contamination.                                                                                                                                                                                                                                                                                                                                                                                                                      | 47           | 0.86%                      |
| CGMP Deviations: Products are underdosed or have an incorrect dosage regime.                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | 44           | 0.80%                      |
| CGMP Deviations: Products were manufactured outside of the controls required by current Good Manufacturing Practices.                                                                                                                                                                                                                                                                                                                                                                                                                            | 43           | 0.78%                      |
| CGMP Deviations: products manufactured under conditions that could impact its product quality.                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 43           | 0.78%                      |
| CGMP Deviations: Products were exposed to temperatures outside of the products labeled storage conditions.                                                                                                                                                                                                                                                                                                                                                                                                                                          | 42           | 0.77%                      |
| cGMP Deviations: Potential product contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).                                                                                                                                                                                                                                                                                                                                                                                                                    | 41           | 0.75%                      |
| cGMP deviations: all products within expiry are being recalled because the firm is discontinuing its stability study program.                                                                                                                                                                                                                                                                                                                                                                                                                        | 37           | 0.67%                      |
| CGMP deviations: Stability testing was not conducted on manufactured sunscreen and hand sanitizer OTC products.                                                                                                                                                                                                                                                                                                                                                                                                                                    | 36           | 0.66%                      |
| CGMP Deviations: These products have been found to be misbranded as unapproved new drugs                                                                                                                                                                                                                                                                                                                                                                                                                                                          | 35           | 0.64%                      |
| Chemical contamination: product contains elevated levels of undeclared lead.                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 35           | 0.64%                      |
| CGMP Deviations: These products have been found to be misbranded as  unapproved new drugs                                                                                                                                                                                                                                                                                                                                                                                                                                                         | 35           | 0.64%                      |
| Non-Sterility: Out of specification results for the sterility test for microbial contamination.                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 34           | 0.62%                      |
| CGMP Deviations: prior to October 1, 2021, environmental and personnel monitoring Out of Action Limit (OOAL) excursions were not being properly investigated                                                                                                                                                                                                                                                                                                                                                                                    | 33           | 0.60%                      |

**Insights from Table 2:**

*   **Microbial Contamination Dominates:** Microbial contamination and penicillin cross-contamination are the leading reasons for recalls, accounting for a significant portion (approximately 17%) of CGMP and impurity-related drug recalls. This highlights the critical importance of maintaining sterile manufacturing environments and preventing cross-contamination.
*   **Temperature Excursions and Stability Issues:**  Several recall reasons relate to temperature excursions during storage and lack of stability data or controls. These point to potential weaknesses in temperature management throughout the drug product lifecycle and insufficient stability testing protocols.
*   **General CGMP Deviations:**  "CGMP Deviations" and "cGMP deviations" appear multiple times as general reasons, suggesting a broad category of manufacturing practice failures.  More specific reasons under this umbrella, such as "following an FDA inspection" or "lack of stability data," provide more granular insights.
*   **Impurity Issues Beyond Microbial:** While microbial contamination is prominent, other impurity issues like "Failed Impurities/Degradation Specifications," "Carcinogen impurity detected," "Presence of NDMA impurity," and "Chemical contamination" also contribute to recalls, indicating a range of chemical and degradation-related quality concerns.
*   **Sterility Assurance:**  "Lack of assurance of sterility" and "Non-Sterility" are significant reasons, reinforcing the importance of robust sterilization processes, especially for sterile drug products.

**Limitations of Insights:**

*   **Missing Ingredient and Manufacturer Data:** Due to the failure of `Analysis Query 2`, `Analysis Query 3`, and `Analysis Query 4`, we could not identify specific drug ingredients or manufacturers disproportionately associated with these recalls. This limits our ability to directly answer the core research question regarding disproportionate associations.
*   **Focus on Recall Reasons:** The analysis is heavily reliant on the "reason_for_recall" field, which may be inconsistently or vaguely documented in some cases. More detailed information about the specific CGMP deviations or impurities would be beneficial for a deeper analysis.

## Validity and Feasibility of the Research Question:

**Validity:**

*   **High Validity:** The research question is highly valid and relevant to drug safety. Drug recalls are a critical indicator of potential safety issues, and understanding the factors contributing to recalls, especially CGMP deviations and impurity issues, is crucial for public health.
*   **Addresses a Significant Problem:**  CGMP deviations and impurities directly impact drug quality and patient safety. Identifying specific ingredients or manufacturers associated with these recalls can lead to targeted interventions and improvements in drug manufacturing and regulation.
*   **Actionable Outcomes:** The research has the potential to generate actionable insights that can inform regulatory bodies, pharmaceutical companies, and healthcare providers about high-risk areas and necessary preventative measures.

**Feasibility:**

*   **Data Availability:** The research question is feasible given the availability of data in the provided database schema. The `enforcements`, `enforcement_openfda`, `drug_openfda`, `products`, and `active_ingredients` tables are designed to capture the necessary information for this analysis.
*   **Partial Success of Strategy:**  While some queries failed, `Analysis Query 1` and `Analysis Query 5` were successfully executed, demonstrating the feasibility of extracting and analyzing relevant recall data. The time trend and recall reason categorization analyses were achievable.
*   **Challenges in Data Linkage (as noted in original strategy):** The original research strategy correctly identified potential challenges in linking tables, particularly between `drug_openfda`, `products`, and `active_ingredients`. The failed queries likely indicate issues with the join logic or data inconsistencies across these tables, which need to be addressed for complete feasibility. The note in the original strategy regarding `spl_set_ids`, `product_ndcs`, and `application_numbers` being array fields and needing careful handling is crucial and might be the root cause of the query failures.
*   **Need for Refinement:**  To fully address the research question, the data linkage strategy needs to be refined. Specifically, debugging and optimizing the joins in `Analysis Query 2`, `Analysis Query 3`, and `Analysis Query 4` are essential. This might involve:
    *   Careful examination of data types and values in linking fields.
    *   Adjusting join conditions to handle array fields correctly (e.g., using array overlap `&&` or `unnest` if necessary).
    *   Exploring alternative linking paths if `spl_set_ids` is not consistently reliable, such as using `product_ndcs` or `application_numbers` as suggested in the initial strategy.

**Conclusion on Validity and Feasibility:**

The research question is **valid** and highly relevant. The research is **partially feasible** with the current data and strategy, as demonstrated by the successful trend analysis and recall reason categorization. However, to fully answer the research question and identify disproportionate associations with ingredients and manufacturers, the **feasibility needs to be enhanced** by resolving the data linkage challenges and refining the SQL queries, particularly for joining across `drug_openfda`, `product_openfda`, and `active_ingredients` tables. Once these technical issues are addressed, the research can be fully executed, and more comprehensive insights can be generated.